Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Ref Type | Abstract | ||||||||||||
PMID | |||||||||||||
Authors | S. Lin Y. Zhang B. Li R. Shi Y. Qiu H. Hua | ||||||||||||
Title | DB-1303, a HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising safety profile and anti-tumor efficacy with differentiation from DS-8201a | ||||||||||||
|
|||||||||||||
URL | https://www.ejcancer.com/article/S0959-8049(22)01040-1/fulltext | ||||||||||||
Abstract Text | Background: DB-1303 is a novel antibody-drug conjugate comprised of trastuzumab biosimilar, enzymatically cleavable peptide-linker, and a proprietary topoisomerase I inhibitor P1003. It is designed to have high plasma stability, low free payload in circulation and wide therapeutic index. Herein, we describe the preclinical profile of DB-1303, including efficacy, pharmacokinetics, and safety. Material and Methods: In vitro cell growth inhibition and in vivo antitumor activities of DB-1303 were evaluated in several Her2-low tumor cell lines and xenograft models. Tumor-bearing mice were used to assess pharmacokinetic and pharmacodynamic characteristic of DB-1303. The mechanism of action for the efficacy was also evaluated. Plasma stability of DB-1303 was determined with rat, monkey, and human plasma. Pharmacokinetic and safety profiles of DB-1303 were evaluated in cynomolgus monkeys. Results: In vitro, DB-1303 selectively binds to and is endocytosed into the lysosome of HER2-positive cells. DB-1303 causes G2/M cell cycle arrest, induces DNA damage, and inhibits cell proliferation in HER2-expressing cells. Importantly, DB-1303 showed inhibitory activity to Her2 low-expressing CAPAN-1 (pancreatic cancer) and Ishikawa (endometrial cancer) cell lines. Under a coculture condition of HER2-positive KPL-4 cells and HER2-negative MDA-MB-468 cells in vitro, DB-1314 inhibited the proliferation of both cells, demonstrating its bystander effect. In vivo, DB-1303 induced dose-dependent tumor growth inhibition and tumor regression in T-DM1-resistant JIMT-1 xenograft model, HER2 low-expressing Ishikawa xenograft and two HER2-low breast cancer PDX models. A single dosing of DB-1303 in NCI-N87 tumor-bearing mice induced significant DNA damage in tumors, and the Cmax of payload in tumor tissues was about 45-fold higher than that in peripheral blood. Pharmacokinetics and safety profiles of DB-1303 were favorable and the highest non-severely toxic dose was 80 mg/kg in cynomolgus monkey study with Q3W dosing of 3 repeated doses. It’s worth noting that, unlike DS-8201a, no interstitial pneumonia was observed in monkeys during the dosing period and recovery period. The payload P1003 poses very low risk of drug-drug interaction. Following administration of DB-1303, systemic P1003 exposure was low and P1003 was cleared rapidly. Conclusions: DB-1303 exhibited potent antitumor activity in both HER2 positive and HER2 low tumor models with a wide therapeutic window. The stable linker in circulation and fast clearance of P1003 may contribute to the superior safety profile of DB-1303. These studies suggest the potential of DB-1303 to address unmet medical needs in HER2 expressing cancers, especially in HER2 low cancers. At the time of presentation, a first-in-human phase 1/2 study in patients with advanced solid tumors is in progress (NCT05150691). |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
DB-1303 | DB1303|DB 1303 | HER2 (ERBB2) Antibody 74 HER2 (ERBB2) Antibody-Drug Conjugate 29 | DB-1303 is an antibody-drug conjugate (ADC) composed of a biosimilar to the ERBB2 (HER2)-targeted antibody Herceptin (trastuzumab) conjugated to the topoisomerase I inhibitor P1003, which potentially leads to growth inhibition of ERBB2 (HER2)-expressing tumor cells and tumor regression (European Journal of Cancer 174 (2022): S91). |
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|